Management of dyslipidaemias –  present and future. Guidelines of the Angiology Section of the Slovak Medical Chamber (2013)

Authors: P. Gavorník  1 3;  A. Dukát 1,3;  Ľ. Gašpar 1,3
Authors‘ workplace: II. interná klinika Lekárskej fakulty UK a UN Bratislava, Slovenská republika, prednosta doc. MU Dr. Ľudovít Gašpar, PhD. 2 Prvé angiologické pracovisko (PAP) II. internej kliniky Lekárskej fakulty UK a UN Bratislava, Slovenská republika, vedúci lekár doc 1
Published in: Vnitř Lék 2013; 59(10): 932-938
Category: Guidelines


The aim of Guidelines of the Angiology Section of the Slovak Medical Chamber is to address a last European guidelines for the management of dyslipidaemias, as well as results in evidence‑based‑ medicine (EBM) in order to assess their contribution to our expanding knowledge on reducing of residual organovascular risk.

Lipid metabolism can be disturbed in different ways, leading to changes in plasma lipoprotein function and/ or levels. This by itself and through interaction with other vascular risk factors and endothelial dysfunction may affect the development of atherosclerosis and other vascular diseases. Therefore, dyslipidaemias cover a broad spectrum of lipid abnormalities, some of which are of great importance in organovascular prevention. Dyslipidaemias may be related to other diseases (secondary dyslipidaemias) or to the interaction between genetic predisposition and environmental factors. Dyslipidaemias may also have a different meaning in certain subgroups of patients which may relate to genetic predisposition and/ or co‑ morbidities. This requires particular attention complementary to the management of the total CV risk. Optimal LDL‑cholesterol levels are the primary strateging task in the therapeutical preventive approaches. However, at present increasing attention has focused on the role of inflamation, levels of HDL‑cholesterol and triglycerides in the process of atherosclerosis. Statins represent basic pillar in dyslipidemia treatment. Despite the intensive management of all conventional vascular risk factors and the intensified treatment with statins, residual organovascular risk remains high. Therefore the interest is focused on finding the place of combined antidyslipidemic treatment and the development of new antidyslipidemics.

Strategies for preventing of organovascular diseases have emphasized vascular risk factors effective modification using treatment approaches supported by evidence‑based‑ medicine (EBM).

Key words:
dyslipidaemia –  management –  organovascular diseases –  combined antidyslipidemic treatment –  new antidyslipidemics – preventive angiology


1. Alberti KG, Eckel RH, Grundy SC et al. Harmonizing the Metabolic Syndrome. A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention, National Heart, Lung and Blood Institute, American Heart Association, World Heart Federation, International Atherosclerosis Society and International Association for the Study of obesity. Circulation 2009; 120: 1640– 1645.

2. Antignani PL, Benedetti‑ Valentini F, Aluigi L et al. Dia­gnosis of vascular diseases. Ultrasound investigations –  Guidelines. Int Angiol 2012; 31 (5 Suppl 1): 1– 79.

3. Armitage J, Bowman L, Wallendszus K et al. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) collaborative group. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double‑blind randomized trial. Lancet 2010; 376: 1658– 1669.

4. Bada V. Výživa ako prevencia KVS chorôb. Kardiol prax 2009; 7: 91– 96.

5. Baigent C, Blackwell I, Emberson J et al. Cholesterol Treatment Trialists (CTT) collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta‑analysis of data from 170,000 participants in 26 randomized trials. Lancet 2010; 376: 1670– 1681.

6. Baigent C, Landray MJ, Reith C et al. SHARP investigators. The effects of lowe‑ ring LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomized trial. Lancet 2011; 377: 2181– 2192.

7. Banegas JR, López‑ Garcia E, Dallongeville J et al. Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J 2011; 32: 2143– 2152.

8. Barter PJ, Caulfield M, Eriksson M et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109– 2122.

9. Bates TR, Connaughton VM, Watts GF et al. Non‑ adherence to statin therapy: a major chal­lenge for preventive cardiology. Expert Opin Pharmacother 2009; 10: 2973– 2985.

10. Berriot‑ Varoqueaux N, Aggerbeck LP, Samson‑ Bouma M et al. The role of microsomal triglyceride transfer protein in abetalipoproteinemia. Ann Rev Nutr 2000; 20: 663– 697.

11. Boden WE, Probstfild JL, Anderson T et al. for AIM‑ HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365: 2255– 2267.

12. Brookes L. Antisense drug ISIS‑ 301012 lowers LDL cholesterol alone and in combination with statins. Medscape Cardiology 2007 [online]. Available from: http:/ / viewarticle/ 556073.

13. Burnett JR, Watts GF. MTP inhibitionas treatment for dyslipidemias: time to deliver or empty promises. Expert Opin Ther Targets 2007; 2: 181– 189.

14. Burnett JR. Drug evaluation: ISIS‑ 301012, an antisense oligonucleotide for the treatment for hypercholesterolemia. Curr Opin Mol Ther 2006; 8: 461– 467.

15. Cannon CP, Shah S, Hayes MD et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363: 2406– 2415.

16. Čavoj V, Mikeš Z, Dukát A. Má kardiovaskulárna rehabilitácia svoje miesto v liečbe pacientov po infarkte myokardu? Kardiol Prax 2004; 2: 239– 242.

17. Čavoj V. Rehabilitácia po infarkte myokardu a revaskularizačných výkonoch. Interná Med 2006; 6: 602– 605.

18. Čavoj V. Kam kráča kardiovaskulárna rehabilitácia na Slovensku. Cardiology 2008; 17: 64– 66.

19. Davidson MH. Squalene synthase inhibitors: a novel target for the management of dyslipidemia. Curr Atheroscler Rep 2007; 9: 78– 80.

20. Dias C, Shaywitz A, Smith B et al. A phase 1, randomized, double‑blind, placebo‑ controlled, ascending single dose study to evaluate the safety, tolerability and pharmacodynamics of AMG145. Circulation 2011; 124: A10701.

21. Diskstein K, Cohen‑ Solal A, Filippatos G et al. ESC Guidelines for the dia­gnosis and treatment of acute and chronic heart failure 2008: The Task Force for the Dia­gnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388– 2442.

22. Duff CJ, Hooper NM. PCSK9: an emerging target for treatment of hypercholesterolemia. Expert Opin Ther Targets 2011; 15: 157– 168.

23. Dukát A, Wawruch M, Mistríková M et al. Súčasnosť liečby, ktorá upravuje hladiny lipidov a význam kombinovanej hypolipidemickej liečby. Interná Med 2012; 12: 539– 544.

24. Dukát A. Čo priniesli nové odporúčania ESC/ EAS pre liečbu dyslipidémií? Interná Med 2012; 12: 90– 91.

25. Dukát A, Filipová S. Komentár SKS k Odporúčaniam Európskej kardiologickej spoločnosti a Európskej asociácie pre aterosklerózu pre liečbu dyslipidémií. Cardiology Lett 2012; 21: 285– 287.

26. Dzúrik R, Spustová V, Gajdoš M. Kyselina acetylsalicylová, statíny alebo ich kombinácia v prevencii náhlych kardiovaskulárnych príhod? Kardiol Prax 2005; 3: 179– 180.

27. Fábryová Ľ. Budúcnosť farmakoterapie dyslipidémií. Interná Med 2012; 12: 254– 260.

28. Fábryová Ľ. Farmakoterapia zameraná na znižovanie LDL cholesterolu. Statíny, kombinácia hypolipidemík a čo ďalej? Cardiology Lett 2012; 21: 420– 427.

29. Farnier M, Averna M, Missault L et al. Lipid‑ altering efficacy of ezetimibe/ simvastatin 10/ 20 mg compared with rosuvastatin 10 mg in high‑risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy –  the IN‑ CROSS study. Int J Clin Pract 2009; 63: 547– 559.

30. Fayad ZA, Mani V, Woodward M et al. Rationale and design of dal‑ PLAQUE: a study asses­sing efficacy and safety of dalcetrapib on progression and regression of atherosclerosis using magnetic resonance imaging and 18F‑ fluo­rodeoxyglucose positron emission tomography/ computed tomography. Am Heart J 2011; 162: 214– 221.

31. Filipová S, Fábryová Ľ, Mikeš Z et al. Aktualizácia lipidového konsenzu‑ 2. Cardiology 2006; 15: 252– 255.

32. Fleg JL, Mete M, Howard BV et al. Effect of statins alone versus statins plus ezetimibe on carotid atherosclerosis in type 2 diabetes: the SANDS (Stop Atherosclerosis in Native Diabetics Study) trial. J Am Coll Cardiol 2008; 52: 2198– 2205.

33. Fox K, Garcia MA, Ardissino D et al. Guidelines on the management on stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J 2006; 27: 1341– 1381.

34. Fruchart JC, Sacks FM, Hermans MP et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in dyslipidaemic patients. Diab Vasc Dis Res 2008; 5: 319– 335.

35. Gajdoš M, Uhliar R. Intenzívna liečba atorvastatínom –  správna voľba u pacientov s akútnym koronárnym syndrómom. Súč Klin Pr 2011; 2: 53– 56.

36. Galajda P, Mokáň M. Aktuálne problémy v oblasti metabolického syndrómu. Ateroskleróza 2012; 16: 238– 243.

37. Gavorník P. Cielené vysvetľovanie cievnych chorôb a cievnych porúch (Projekt CIEVY). „Srdcovocievne choroby“, „srdcovo‑ cievne choroby“, „srdcovocievny systém“, srdcovo‑ cievny systém“, „srdcovo‑ cievne abnormality“, „srdcovocievne poruchy“, „kardiovaskulárne choroby“, „kardiovaskulárna medicína“ –  počujeme a čítame to denne. Vieme, o čo ide? Cardiology 2009; 18: K/ C84– K/ C85.

38. Gavorník P. Všeobecná angiológia. Angiologická propedeutika. Cievne choroby. Bratislava: Univerzita Komenského –  Vydavateľstvo UK 2001.

39. Gavorník P, Dukát A, Gašpar Ľ et al. Odporúčania Sekcie angiológov SLK pre manažment artériovej hypertenzie (2011). Cievy –  páchateľky, nástroje i obete artériovej hypertenzie (cievnej choroby cievnych chorôb). Ateroskleróza 2011; 15: 79– 84.

40. Gavorník P, Dukát A, Gašpar Ľ. Manažment stabilnej anginy pectoris a iných foriem chronickej kardiovaskulárnej artériovej choroby. Vnitř Lék 2012; 58: CD29– CD36.

41. Gavorník P, Dukát A, Gašpar Ľ et al. Endotelová dysfunkcia a multiorgánovomultivaskulárna (polyorgánovopolyvaskulárna) choroba. Forum Diab 2012; 1: 77– 85.

42. Gavorník P. Artériová hypertenzia: Cievy –  páchateľky, nástroje i obete artériovej hypertenzie. Odporúčania podľa Sekcie angiológov SLK pre manažment artériovej hypertenzie. I‑ med 2012; 2: 1– 38 [online]. Prístupné na: http:/ / www.i‑ Internistickediscipliny/ Angiologia.

43. Gavorník P. Ateroskleróza a iné choroby tepien. Bratislava: Univerzita Komenského –  Vydavateľstvo UK 1999.

44. Gavorník P. Efektívna racionálna prevencia a liečba orgánovocievnych artériových ischemických chorôb v preventívnej vaskulárnej medicíne. I‑ med 2012; 2: 1– 30 [online]. Prístupné na: http:/ / www.i‑ Internistickediscipliny/ Angiologia.

45. Gavorník P. Končatinovocievne ischemické choroby. B 2.1: 1– 92. In: Gavorník P, Hrubiško M, Rozborilová E (eds). Diferenciálna dia­gnostika kardiovaskulárnych, respiračných a hematologických ochorení I. Bratislava: Dr. Josef Raabe 2010.

46. Gavorník P. Obliterujúce choroby artérií a končatinovocievna ischemická choroba. Nová klinicko‑etiologicko‑anatomicko‑patofyziologická (CEAP) klasifikácia. Cardiology 2010; 19: 201– 213.

47. Gavorník P. Orgánovovaskulárne artériové ischemické choroby, ateroskleróza a iné artériové choroby. 1. časť: Ateroskleróza. I‑ med 2012; 2: 1– 24 [online]. Prístupné na: http:/ / www.i‑ Internistickediscipliny/ Angiologia.

48. Gavorník P. Orgánovovaskulárne artériové ischemické choroby, ateroskleróza a iné artériové choroby. 2. časť: Nonaterosklerotické artériové choroby. I‑ med 2012; 2: 1– 133 [online]. Prístupné na: http:/ / www.i‑ Internistickediscipliny/ Angiologia.

49. Gavorník P. Vaskulárna endotelová dysfunkcia –  etiopatogenéza, základné dia­gnostické metódy a liečebné možnosti. Gen Angiol 2002; 2: 59– 66.

50. Goldberg RB, Guyton JR, Mazzone T et al. Ezetimib/ simvastatin vs. atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia: the VYDAL study. Mayo Clin Proc 2006; 81: 1570– 1588.

51. Goncalvesová E. Refraktérne srdcové zlyhávanie. Cardiology 2007; 16: 64– 67.

52. Gonsorčík J, Gibarti C, Diab AY et al. Čo očakávame od MDCT koronarografie u nediabetických hypertonikov? Cardiology 2009; 18 (Suppl 1): 14S.

53. Gotto AM, Moon JE. Management of cardiovascular risk: importance of meeting lipid targets. Am J Cardiol 2012; 110 (Suppl): 3A– 14A.

54. Gotto AM, Moon JE. Recent clinical study of the effects of lipid‑ modifying therapies. Am J Cardiol 2012; 110 (Suppl): 15A– 26A.

55. Graham I, Atar D, Borch‑ Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts). Eur Heart J 2007; 28: 2375– 2414.

56. Hamm CW, Bassand JP, Agewall S et al. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST‑segment elevation. The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST‑segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2999– 3054.

57. Hoefner DM, Hodel SD, O’Brien JF et al. Development of a rapid quantitative method for LDL subfraction with use of the Quantimetrix Lipoprint LDL system. Clin Chem 2001; 472: 266– 274.

58. Hricák V, Janota T, Murín J et al. Statíny u pacientov s akútnym kopronárnym syndrómom. Konsenzus pracovných skupín akútnej kardiológie SKS a ČKS pre indikáciu a dávkovanie statínov. Cardiology Lett 2011; 20: 500– 501.

59. Chapman MJ, Ginsberg NH, Amarenco P et al. Triglyceride‑ rich lipoproteins and high‑density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011; 32: 1345– 1361.

60. Charlton‑ Menys V, Durrington PN. Squalene synthase inhibitors: clinical pharmacology and cholesterol‑ lowering potential. Drug 2007; 67: 11– 16.

61. Kastelein JJ, Akdim F, Stroes ES et al. ENHANCE investigators. Simvastatin with or with­out ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431– 1443.

62. Kastelein JJ, Luscher TF, Taddei S et al. Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease –  the dal‑ VESSEL randomized clinical trial. Curr Med Res Opin 2011; 27: 141– 150.

63. Kollár J, Turay J, Kupperová Ľ. Národný cholesterolový edukačný program. Ateroskleróza 2003; 7: 90– 93.

64. Kollár J. Ateroskleróza –  tuky –  život či naša záhuba? Dá sa pred ňou chrániť? Prešov: Opal 1993.

65. Kollár J. Inzulínom indukované gény v regulácii intracelulárnej syntézy sterolov. Ateroskleróza 2012; 16: 313– 327.

66. Kuchta M. Probio­tické potraviny. In: Kuchta M, Pružinec P et al (eds). Probio­tiká, ich miesto a využitie v medicíne. Bratislava: Bonus CCS 2006: 16– 22.

67. LaRossa JC, Grundy SM, Waters DD et al. Treating to New Targets (TNT) investigators. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1426– 1435.

68. Lazúrová I, Dravecká I. Syndróm polycystických ovárií z pohľadu internistu. Interná Med 2012; 12: 6– 9.

69. Li AC, Binder CJ, Gutierrez A et al. Differential inhibition of macrophage foam‑ cell formation and atherosclerosis in mice by PPAR alfa, beta/ delta and gamma. J Clin Invest 2004; 114: 1564– 1576.

70. Ma K, Cilingiroglu M, Otvos JD et al. Endothelial lipase is major genetic determinant for high densily lipoprotein concentration, structure, and metabolism. Proc Nat Acad Sci USA 2003; 100: 2748– 2753.

71. Maciejewski S, Hilleman D. Effectiveness of a fenofibrate 145–  mg nanoparticle formulation compared with the standard 160 mg tablet in patients with coronary heart disease and dislipidemia. Pharmacotherapy 2008; 28: 570– 575.

72. Maďarič J. Periférne artériové obliterujúce ochorenie u pacientov s koronárnou chorobou srdca –  ako agresívny byť v dia­gnostike a liečbe? Kardiol Prax 2010; 8: 205– 211.

73. Mancia G, De Backer G, Dominiczak H et al. Management of Arterial Hypertension of the European Society of Hypertension; European Society of Cardiology. 2007 Guidelines for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105– 1187.

74. Mancia G, Laurent S, Agabiti‑ Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121– 2158.

75. Martin SS, Metkus TS, Horne A et al. Waiting for the National Cholesterol Education Program Adult Treatment Panel IV Guidelines, and in the meantime, some challenges and recommendations. Am J Cardiol 2012; 110: 307– 313.

76. McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the dia­gnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Dia­gnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787– 1847.

77. Mokáň M. Hypoglykémia. Vnitř Lék 2008; 54: 387– 394.

78. Molčányiová A. Beneficial effect of simvastatin treatment on LDL oxidation and antioxidant protection is more pronounced in combined hyperlipidemia than in hypercholesterolemia. Pharmacol Res 2006; 54: 203– 207.

79. Morais J, Neyer G, Muniz N. Measurement and Distribution of HDL subclasses with the new Lipoprint® HDL method. Presented at AACC international congress of clinical chemistry. Philadelphia, PA, June 2003.

80. Moutzouri E, Kei A, Elisaf MS et al. Management of dyslipidemias with fibrates, alo and in combination with statins: role of delayed‑ release fenofibric acid. Vasc Health Risk Manag 2010; 6: 525– 539.

81. Navab M, Anantharamaiah GM, Redy ST et al. Apolipoprotein A‑ I mimetic peptides and their role in atherosclerosis prevention. Nat Clin Pract Cardiovasc Med 2006; 3: 540– 547.

82. Nilsson PM. ACCORD and risk‑factor con­trol in type 2 diabetes. N Engl J Med 2010; 362: 1628– 1630.

83. Nissen SE, Tardif JC, Nicholls SJ et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304– 1316.

84. Nissen SE, Tsunoda T, Tuzcu EM et al. Effect of recombinant apo A‑ I Milano in coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290: 2292– 2300.

85. Oravec S, Dukat A, Gavornik P et al. Atherogenic normolipidemia –  a new phenomenon in the lipoprotein of clinically healthy subjects. Neuroendocrinol Lett 2011; 32: 317– 321.

86. Oravec S, Dukat A, Gavornik P et al. Contribution of the atherogenic lipoprotein profile to the development of arterial hypertension. Bratisl Lek Listy 2010; 112: 4– 7.

87. Oravec S, Dukát A, Gavorník P et al. Zmeny v lipoproteínovom spektre pri končatinovocievnej ischemickej chorobe. Vnitř Lék 2010; 56: 620– 623.

88. Oravec S, Mikl J, Gruber K et al. A Non‑ atherogenic and atherogenic lipoprotein profile in individuals with dyslipoproteinemia. In: Frank S, Kostner H (eds.) Lipoproteins –  Role in Health and Diseases. Novi Sad: InTech Prepress 2012: 73– 94.

89. Payer J, Baňárová A. Vplyv testosterónu na kardiovaskulárne ochorenia u mužov. Vnitř Lék 2010; 56: 702– 708.

90. Pedersen TR, Faergeman O, Kastelein JJet al. Incremental Decrease in Endpoints through Aggresive Lipid Lowering (IDEAL) Study Group. High‑dese atorvastatin vs usual‑dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294: 2437– 2445.

91. Pella D. Statíny –  sú všetky rovnaké? Kardiol Prax 2012; 10: 184– 188.

92. Perk J, De Backer G, Gohlke H et al. Joint ESC Guidelines. European Guidelines on cardiovascular disease prevention in clinical practice (Version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2012; 33: 1635– 1701.

93. Petrášová D, Bertková I, Koprovičová J. Monitoring rizikových faktorov aterosklerózy u detí s familiárnou záťažou. Čas Lék Česk 2012; 151: 35.

94. Preiss D, Seshasai SR, Welsh P et al. Risk of incident diabetes with intensive‑dose compared with moderate‑dose statin therapy. JAMA 2011; 305: 2556– 2564.

95. Preiss D, Tikkanen MJ, Welsh P et al. Lipid‑ modifying therapies and risk of pancreatitis. A metaanalysis. JAMA 2012; 308: 804– 811.

96. Pullmann R, Pavlovič M. Laboratórne nálezy a ich klinická interpretácia: parametre laboratórnych vyšetrení, dia­gnostické stratégie a diferenciálna dia­gnostika. Bratislava: Dr. Josef Raabe 2010.

97. Rašlová K, Filipová K, Mikeš Z et al. Odpo­rúčania pre optimálnu dia­gnostiku a liečbu dyslipoproteinémií u dospelých –  “Lipidový konsenzus –  2”. Interná Med 2003; 3: 10– 18.

98. Regitz‑ Zagrosek V, Lundquist CB, Borghi Cet al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 3147– 3197.

99. Reiner Ž, Catapano AL, De Backer G et al. ESC/ EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32: 1769– 1818.

100. Rooke TW, Hirsch AT, Misra S et al. 2011 ACCF/ AHA Focused Update of the Guideline for the Management of Patients With Peripheral Artery Disease (Updating the 2005 Guideline). A Report of the American College of Cardiology Foundation/ American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011; 58: 2020– 2045.

101. Rosenbaum D, Dallongeville J, Sabouret P et al. Discontinuation of statin therapy due to muscular side effects: A survey in real life. Nutr Metabol Cardiovasc Dis 2012; 10: 1– 5.

102. Rosipal Š, Debreová M. Screening and treatment for pediatric dyslipoproteinemias regarding the premature atherosclerosis in clinical practice. The Slovak guideline. Ateroskleróza 2011; 15: 85– 94.

103. Rydén L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. The Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 2013. [ahead of print].

104. Saurav A, Kaushik M, Mohiuddin SM. Fenofibric acid for hyperlipidemia. Expert Opin Pharmacother 2012; 13: 717– 722.

105. Scott J. The liver X receptor and atherosclerosis. N Engl J Med 2010; 357: 2195– 2197.

106. Schwartz GG, Olsson AG, Ballantyne MC et al. Rationale and design of the dal‑ OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome. Am Heart J 2009; 158: 896– 901.

107. Smith SC Jr, Benjamin EJ, Bonow RO et al. AHA/ ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update. A Guideline From the American Heart Association and American College of Cardiology Foundation. J Am Coll Cardiol 2011; 58: 2432– 2446.

108. Stein EA, Mellis S, Yancopoulos GD et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108– 1118.

109. Šimková I, Chňupa P. Manažment aortálnej stenózy. Kardiol Prax 2011; 9: 81– 85.

110. Šimurka P. Liečba statínmi v detskom veku. Pediatria 2011; 6: 100– 101.

111. Tendera M, Aboyans V, Bartelink ML et al. ESC Guidelines on the dia­gnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries. The Task Force on the Dia­gnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32: 2851– 2906.

112. Keech A, Simes RJ, Barter P et al. Effects of long‑term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005; 366: 1849– 1861.

113. Tkáč I, Fábryová Ľ, Rašlová K. Manažment dyslipidémií u pacientov s diabetes mellitus. Vyjadrenie stanoviska Slovenskej diabetologickej spoločnosti a Slovenskej asociácie aterosklerózy. Interná Med 2006; 6: 45– 50.

114. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes mellitus (ACCORD) trial. Circulation 2010; 122: 850– 852.

115. Turay J. Prevencia srdcovo‑ cievnych ochorení. Bratislava: H.C.P. Slovakia 2003.

116. Van de Werf F, Bax J, Betriu A et al. Management of acute myocardial infarction in patients presenting with persistent ST‑segment elevation: The Task Force on the management of ST‑segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 2008; 29: 2909– 2945.

117. Villines TC, Stanek EJ, Devine PJ et al. The ARBITER 6-HALTS trial (Arterial Biology for the Treatment Effects of reducing Cholestererol 6- HDL and LDL Treatment Strategies in atherosclerosis): final results and the impact of medication adherence, dose and treatment duration. J Am Coll Cardiol 2010; 55: 2721– 2726.

118. Prasad K. Rosveratrol, wine, and atherosclerosis. Int J Angiol 2012; 21: 7– 18.

119. Whayne TF. Atherosclerosis: Current status of prevention and treatment. Int J Angiol 2011; 20: 213– 222.

120. Whayne TF. Vitamin D: popular cardiovascular supplement but benefit must be evaluated. Int J Angiol 2011; 20: 63– 72.

121. Whayne TF. Metabolic syndrome, peripheral vascular disease and coronary artery disease: A concise review. Int J Angiol 2010; 19: e96– e99.

122. Landmesser U. The difficult search for a ‘partner’ of statins in lipid‑ targeted prevention of vascular events: the re‑emergence and fall of niacin. Eur Heart J 2013; 34: 1254– 1257.

123. Hovingh GK, Davidson MH, Kastelein JJ et al. Dia­gnosis and treatment of familial hypercholesterolaemia. Eur Heart J 2013; 34: 962– 971.

124. Zheng C, Azcutia V, Aikawa E et al. Statins suppress apolipoprotein CIII‑induced vascular endothelial cell activation and monocyte adhesion. Eur Heart J 2013; 34: 615– 624.

125. Soška V, Vaverková H, Vrablík M et al. Stanovisko výboru ČSAT k doporučením ESC/ EAS pro dia­gnostiku a léčbu dyslipidemií z roku 2011. Vnitř Lék 2013; 59: 120– 126.

Diabetology Endocrinology Internal medicine
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.


Don‘t have an account?  Create new account